Advocacy for Homeopathy Working Group
The Food and Drug Administration (FDA) had a two-day listening session in April 2015 that was defined as an opportunity for experts and members of the public to help the FDA decide how it should regulate homeopathic products. In September 2015, the Federal Trade Commission (FTC) convened a workshop to examine how homeopathic drugs are marketed to consumers. The workshop was followed by issuance of a new “Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs.” In September 2016, the FDA issued a press release warning that homeopathic teething tablets might not be safe.
In response to these events, the Advocacy for Homeopathy Working Group (AHWG) was convened in 2017 to bring together national and state homeopathic organizations to speak with a unified voice to advocate for continued access to and use of homeopathic products and services.
The AHWG continues to meet monthly with a focus on the following goals:
- Implement a unified media/communication plan with specific strategies for messaging and reaching defined audiences to support advocacy efforts.
- Use existing organizational communication mechanisms to ensure that everyone has correct and up-to-date information on emerging issues that affect homeopathy.
- Identify existing materials and resources on homeopathy to support advocacy efforts.
- Develop materials as needed that focus on homeopathy as a safe, effective, affordable healthcare solution for many of the major issues facing healthcare today (e.g., chronic disease, autoimmune disease, infectious disease, antibiotic resistance, pain management, addiction, underserved populations, etc.).
- Create response templates for all homeopathic organizations to use and disseminate for advocacy efforts related to specific issues as they arise (e.g., FDA, FTC, etc.).